Sun Pharma shares hit new 52-week high as three-month returns top 17 percent

Sun Pharmaceutical Industries shares climbed to a new 52-week high of Rs 1955.0 during early trading on July 15, 2026. The stock decisively surpassed its previous record of Rs 1953.9, marking a gain of 0.6383 percent in the session. By mid-morning, the stock was trading at Rs 1949.80, maintaining a positive trajectory with a 0.38 percent increase.

This latest peak extends a robust rally for the pharmaceutical giant, underscoring its resilience in the broader market. Over the past three months, the stock has delivered a substantial return of 17.58 percent. Such consistent upward movement highlights strong growth potential and sustained buying interest in the equity.

Trading activity has also intensified alongside the recent price appreciation, confirming the strength of the breakout. Recent session volume reached 2,822,124 shares, comfortably exceeding the average of 2,468,817 shares recorded over the past week. Furthermore, the three-day simple moving average currently stands at Rs 1937.93, indicating stable near-term technical performance.

For investors evaluating the company's current valuation, the stock carries a price-to-earnings ratio of 40.75. Concurrently, earnings per share are reported at 47.84. These fundamental metrics suggest the market is actively pricing in continued earnings growth, a dynamic frequently observed for established market leaders in the healthcare sector.

The company's aggregate market capitalization now stands at 467,726.36, reflecting its massive scale. This milestone reinforces Sun Pharma's position as a definitive heavyweight in the Indian equity market. Market professionals will be watching closely to see if the stock can consolidate and hold above the Rs 1937 support level following this fresh breakout.

The current bullish momentum follows a solid close in the previous trading session. Shares ended that day at Rs 1921.40, reflecting a 1.1 percent increase on a trading volume of 1,573,176 shares. This sequential strength provides a firm foundation for the stock's ongoing upward valuation.